Amphastar signs exclusive license with Nanjing Anji for three peptide products in US and Canada
On August 8, 2025, Amphastar entered into an exclusive license agreement with Nanjing Anji Biotechnology for three peptide-based products in the United States and Canada, and announced it on August 12, 2025. Amphastar paid $0.75 million in earnest money and a $5.25 million upfront payment, with further development and sales milestone payments of up to $42 million and $225 million, contingent on achieving those milestones. The filing ties the deal to Amphastar's pipeline expansion, but the payments depend on future milestones and commercial results.
Key points
- Agreement signed August 8, 2025; covers three identified peptide products in the US and Canada.
- Upfront costs: $0.75 million earnest money and $5.25 million upfront payment to Anji.
- Potential payments: up to $42 million in development milestones and up to $225 million in sales milestones.
- Royalties owed by Amphastar are capped at $22.5 million per calendar year and $60 million accumulated per product.
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.